Baylor Research Institute

Virginia Pascual

Jacques F Banchereau

Anna Karolina Palucka

Kiley Prilliman

Jacques Branchereau

The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha ('IFN&#x3b1;') protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFN&#x3b1; protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFN&#x3b1; subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFN&#x3b1; related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.

Anti-inteferon alpha monoclonal antibodies and methods for use

The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1&#x3b2;.

Compositions and methods for the systemic treatment of arthritis

The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha ('IFN&#x3b1;') protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, 1, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFN&#x3b1; protein subtype D. Examples of bioactivity for measurement include activation of the M&#xd7;A promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFN&#x3b1; subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFN&#x3b1; related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.

Growing community of inventors

Dallas, TX, United States of America

Virginia Pascual